Linda A. DiMeglio, MD

Linda DiMeglio, MD, MPH | Image Credit: Riley Children's Health

Linda DiMeglio, MD, MPH, is a professor of pediatrics and the division chief at Indiana University School of Medicine.

Articles by Linda A. DiMeglio, MD

Diabetes Dialogue: The Push for Early-Stage T1D Screening and Treatment, With Linda DiMeglio, MD, MPH

ByDiana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES,Linda A. DiMeglio, MD

April 23rd 2026

Linda DiMeglio, MD, MPH, joins the show to discuss the growing movement towards screening and testing for T1D at an early stage.

Bridging the Gap for T1D Management

BySteve Edelman, MD,Linda A. DiMeglio, MD,Egils K. Bogdanovics, MD,Justin M. Gregory, MD, MSC,Schafer Boeder, MD

August 30th 2023

Expert endocrinologists provide final thoughts on addressing unmet needs and improving the management of T1D.

Investigational Approaches for Treating T1D

BySteve Edelman, MD,Linda A. DiMeglio, MD,Egils K. Bogdanovics, MD,Justin M. Gregory, MD, MSC,Schafer Boeder, MD

August 30th 2023

Schafer Boeder, MD, and Egils K. Bogdanovics, MD, share approaches to prevention, preservation, and replacement therapies for the treatment of T1D.

Improving Access to Teplizumab and Future Treatments of T1D

BySteve Edelman, MD,Linda A. DiMeglio, MD,Egils K. Bogdanovics, MD,Justin M. Gregory, MD, MSC,Schafer Boeder, MD

August 23rd 2023

Experts in endocrinology share challenges of patient access to type 1 diabetes treatment as well as resources to combat these challenges.

Long-Term Monitoring of Teplizumab in T1D

BySteve Edelman, MD,Linda A. DiMeglio, MD,Egils K. Bogdanovics, MD,Justin M. Gregory, MD, MSC,Schafer Boeder, MD

August 23rd 2023

Expert endocrinologists discuss implementing long-term monitoring of patients being treated with teplizumab for type 1 diabetes and review the PROTECT study for patients who are newly diagnosed with T1D.

Efficacy of Teplizumab in Clinical Trials

BySteve Edelman, MD,Linda A. DiMeglio, MD,Egils K. Bogdanovics, MD,Justin M. Gregory, MD, MSC,Schafer Boeder, MD

August 16th 2023

Egils K. Bogdanovics, MD, and the expert panel review the TN10 study data on the efficacy of teplizumab in delaying the progression of T1D, which led to the drug’s approval from the FDA.

Use of Teplizumab in Delaying T1D

BySteve Edelman, MD,Linda A. DiMeglio, MD,Egils K. Bogdanovics, MD,Justin M. Gregory, MD, MSC,Schafer Boeder, MD

August 16th 2023

Justin M. Gregory, MD, MSCI, provides an overview of the mechanism of action of teplizumab and its use in delaying T1D.

Interpreting T1D Antibody Test Results

BySteve Edelman, MD,Linda A. DiMeglio, MD,Egils K. Bogdanovics, MD,Justin M. Gregory, MD, MSC,Schafer Boeder, MD

August 9th 2023

Egils K. Bogdanovics, MD, and Schafer Boeder, MD, discuss interpreting antibody test results for type 1 diabetes and provide recommendations for retesting for those who have a negative test or have only 1 antibody present.

T1D Screening Options

BySteve Edelman, MD,Linda A. DiMeglio, MD,Egils K. Bogdanovics, MD,Justin M. Gregory, MD, MSC,Schafer Boeder, MD

August 9th 2023

Linda A. DiMeglio, MD, reviews screening options for patients with a family history of T1D, highlighting TrialNet.

Clinical Signs Leading to Diagnostic Testing for T1D

BySteve Edelman, MD,Linda A. DiMeglio, MD,Egils K. Bogdanovics, MD,Justin M. Gregory, MD, MSC,Schafer Boeder, MD

August 2nd 2023

Expert endocrinologists discuss the clinical symptoms that prompt testing for T1D, as well the diagnostic testing tools that are available in clinical practice.